Webinar 2: Initiating patients with GW CBD
Webinar 2: Managing adverse events and determining the optimal dose of GW CBD
Webinar 2: Initiating GW CBD in patients who have previously received a non-regulatory approved cannabis-based product
Webinar 2: Panel discussion and audience Q & A
Webinar 1: GW CBD patient profile
Webinar 1: Starting and maintaining patients on GW CBD and managing adverse events
Webinar 1: GW CBD in patients who have tried or are currently receiving non-regulatory approved cannabis-based products
Elizabeth Thiele provides an overview of the diverse patient profiles of individuals with epilepsy who may benefit from GW CBD treatment, and how to initiate and escalate dosing, and manage adverse events.
Bernhard Steinhoff describes the characteristics, disease history and markers of responsiveness for patients who may benefit from cannabidiol treatment, in addition to the management of adverse events and concomitant medications.
Please Select A Video:
Overview & Learning Objectives
Cannabidiol (Epidyolex®, GW CBD) is indicated for use as an adjunctive therapy, in conjunction with clobazam, for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients ≥2 years of age.1 Here we present a webinar discussion and summary on the shared experiences of six leading physicians on the use of GW CBD for treating these rare epilepsies.
After watching this touchMEETING HIGHLIGHTS, you should be able to:
- Describe some of the diverse profiles of patients who may benefit from cannabidiol
- Understand how to initiate GW CBD and reach optimal dosing
- Discuss potential strategies to manage patients experiencing adverse events (AEs)
- Understand how to manage patients with previous or current experience of non-regulatory approved cannabis-based products
Adverse events should be reported according to local regulations. For the UK, reporting forms and information can be found on the MHRA yellow card site at mhra.gov.uk/yellowcard target or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to GW pharma on email@example.com.
EMA. Epidyolex Summary of product characteristics Available at: https://www.ema.europa.eu/en/documents/product-information/epidyolex-epar-product-information_en.pdf (accessed August 2020).
- For additional resources and patient cases, please visit the GW Pharmaceuticals Epilepsy Focus site: https://www.epilepsy-focus.co.uk/